First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval

In August 2017, the FDA took historic action in granting the first approval of gene therapy to tisagenlecleucel. This landmark step brought CAR T-cell therapy to the commercial space and heralded a new era in managing refractory B-cell malignancies and FDA oversight of gene-modified therapies.

See related article by O'Leary et al., p. 1142

http://bit.ly/2GIbPrD